Merck & Co. (MRK) 8-K Schering-plough Reports Financial Results for 2005 Fourth Quarter, Full Year

EXHIBIT 99.2

SCHERING-PLOUGH CORPORATION
STATEMENTS OF CONSOLIDATED OPERATIONS
(Dollars in Millions, except EPS)
(Unaudited)

	2005																					2004
	1st			2nd			6			3rd			9			4th						1st			2nd			6			3rd			9			4th						4th Qtr.			12 Mos.
	Qtr.			Qtr.			Mos.			Qtr.			Mos.			Qtr.			Year			Qtr.			Qtr.			Mos.			Qtr.			Mos.			Qtr.			Year			vs			vs
	$			$			$			$			$			$			$			$			$			$			$			$			$			$			4th Qtr.			12 Mos.
Net Sales		2,369			2,532			4,900			2,284			7,184			2,324			9,508			1,963			2,147			4,110			1,978			6,088			2,184			8,272			6	%		15	%
Cost of Sales		889			867			1,756			775			2,531			815			3,346			740			790			1,530			711			2,241			829			3,070			(2	%)		9	%
Gross Margin		1,480			1,665			3,144			1,509			4,653			1,509			6,162			1,223			1,357			2,580			1,267			3,847			1,355			5,202			11	%		18	%
Total SG&A		1,081			1,116			2,197			1,064			3,261			1,114			4,374			914			979			1,893			892			2,785			1,026			3,811			9	%		15	%
Research & Development 1/		384			442			825			566			1,391			474			1,865			372			451			824			378			1,201			406			1,607			17	%		16	%
Other Expense/(Income), Net		17			(8	)		9			—			9			(5	)		5			36			43			78			34			112			33			146
Special Charges 2/		27			259			286			6			292			2			294			70			42			112			26			138			15			153
Equity Income from Cholesterol Joint Venture		(220	)		(170	)		(389	)		(215	)		(605	)		(268	)		(873	)		(78	)		(77	)		(154	)		(95	)		(249	)		(98	)		(347	)
Income/(Loss) before Income Taxes		191			26			216			88			305			192			497			(91	)		(81	)		(173	)		32			(140	)		(27	)		(168	)
Income Tax Expense/(Benefit) 3/		64			74			138			23			162			66			228			(18	)		(16	)		(35	)		6			(28	)		807			779
Net Income/(Loss)		127			(48	)		78			65			143			126			269			(73	)		(65	)		(138	)		26			(112	)		(834	)		(947	)
Preferred Stock Dividends		22			22			43			22			65			22			86			—			—			—			12			12			22			34
Net Income/(Loss) Available to Common Shareholders		105			(70	)		35			43			78			104			183			(73	)		(65	)		(138	)		14			(124	)		(856	)		(981	)
Diluted Earnings/(Loss) per Common Share		0.07			(0.05	)		0.02			0.03			0.05			0.07			0.12			(0.05	)		(0.04	)		(0.09	)		0.01			(0.08	)		(0.58	)		(0.67	)
Avg. Shares Outstanding- Diluted		1,480			1,476			1,482			1,487			1,483			1,487			1,484			1,471			1,472			1,471			1,475			1,472			1,473			1,472
Actual Shares Outstanding		1,475			1,476			1,476			1,478			1,478			1,479			1,479			1,472			1,472			1,472			1,472			1,472			1,474			1,474
Ratios To Net Sales
Net Sales		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of Sales		37.5	%		34.2	%		35.8	%		34.0	%		35.2	%		35.1	%		35.2	%		37.7	%		36.8	%		37.2	%		35.9	%		36.8	%		37.9	%		37.1	%
Gross Margin		62.5	%		65.8	%		64.2	%		66.0	%		64.8	%		64.9	%		64.8	%		62.3	%		63.2	%		62.8	%		64.1	%		63.2	%		62.1	%		62.9	%
Total SG&A		45.6	%		44.1	%		44.8	%		46.6	%		45.4	%		47.9	%		46.0	%		46.6	%		45.6	%		46.1	%		45.1	%		45.7	%		47.0	%		46.1	%
Research & Development		16.2	%		17.4	%		16.8	%		24.8	%		19.4	%		20.4	%		19.6	%		19.0	%		21.0	%		20.0	%		19.1	%		19.7	%		18.6	%		19.4	%
Income/(Loss) Before Income Taxes		8.0	%		1.0	%		4.4	%		3.8	%		4.2	%		8.3	%		5.2	%		(4.6	%)		(3.8	%)		(4.2	%)		1.6	%		(2.3	%)		(1.3	%)		(2.0	%)
Net Income/(Loss)		5.3	%		(1.9	%)		1.6	%		2.8	%		2.0	%		5.4	%		2.8	%		(3.7	%)		(3.0	%)		(3.4	%)		1.3	%		(1.8	%)		(38.2	%)		(11.4	%)

Note: The Company noted that it incurs substantial costs, such as selling, general and administrative costs, that are not reflected in the “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough.
1/	Research and development for the twelve months ended December 31, 2005 includes an R&D payment of $124 million, before a tax benefit of $6 million, to Centocor, Inc. for the Company’s exercise of its right to develop and commercialize golimumab, a fully human monoclonal antibody being developed as a therapy for the treatment of rheumatoid arthritis and other immune-mediated inflammatory diseases.
	Research and development in 2004 includes an $80 million upfront payment in conjunction with the licensing from Toyama Chemical Company Ltd. of garenoxacin, a quinolone antibiotic in development.
2/	Special charges for the twelve months ended December 31, 2005 includes an addition of $250 million to the Company’s litigation reserves relating to the Massachusetts investigation and previously disclosed investigations and litigation relating to the company’s practices regarding average wholesale price by the Department of Justice and certain states.
	Special charges for the twelve months ended December 31, 2004 included $119 million of employee termination costs, as well as $27 million of asset impairment charges and $7 million of closure costs primarily related to a small European research-and-development facility.
3/	Tax expense during 2005 primarily related to foreign tax expense as the Company did not recognize the benefit of U.S. tax operating losses.
	The Company’s full year tax provision includes a benefit of approximately $42 million related to tax expense recorded in 2004 related to planned earnings repatriations under the American Jobs Creation Act (AJCA).
	This adjustment of tax expense associated with repatriation under the AJCA is the result of an IRS Notice issued by the U.S. Treasury in August 2005. In the fourth quarter of 2004, the Company recorded the estimated charge associated with the repatriation of funds under the American Jobs Creation Act.

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
CONSOLIDATED SALES
(Dollars in Millions)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th				4th Qtr.			12 Mos.
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		vs			vs
	$		$		$		$		$		$		$		$		$		$		$		$		$		$		4th Qtr.			12 Mos.
Prescription Pharm:		1,846		1,975		3,820		1,840		5,660		1,904		7,564		1,481		1,644		3,125		1,556		4,681		1,737		6,417		10	%		18	%
U.S.		549		609		1,157		597		1,755		600		2,355		411		495		906		518		1,424		584		2,007		3	%		17	%
International		1,297		1,366		2,663		1,243		3,905		1,304		5,209		1,070		1,150		2,220		1,037		3,257		1,153		4,410		13	%		18	%
Consumer Health Care:		330		330		660		235		895		198		1,093		312		317		629		239		868		217		1,085		(9	%)		1	%
OTC:		162		162		324		129		453		103		556		157		150		306		150		456		121		578		(15	%)		(4	%)
OTC Claritin *		116		133		248		92		340		54		394		117		117		234		110		344		75		419		(29	%)		(6	%)
Other OTC		46		29		76		37		113		49		162		40		32		72		41		112		46		159		7	%		2	%
Foot Care:		84		89		173		85		258		75		333		76		89		166		86		252		79		331		(5	%)		1	%
Sun Care:		84		79		163		21		184		20		204		79		78		157		3		160		17		176					16	%
Animal Health:		193		227		420		209		629		222		851		170		186		356		183		539		230		770		(4	%)		11	%
U.S.		44		54		98		68		166		50		216		41		36		77		56		133		61		194		(18	%)		11	%
International		149		173		322		141		463		172		635		129		150		279		127		406		169		575		2	%		10	%
Total Consolidated:		2,369		2,532		4,900		2,284		7,184		2,324		9,508		1,963		2,147		4,110		1,978		6,088		2,184		8,272		6	%		15	%
U.S.		897		970		1,866		886		2,752		837		3,589		738		827		1,565		800		2,365		854		3,219		(2	%)		11	%
International		1,472		1,562		3,034		1,398		4,432		1,487		5,919		1,225		1,320		2,545		1,178		3,723		1,330		5,053		12	%		17	%

* Includes net sales of Claritin in Canada.

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)

	Global Prescription Pharm							U.S.							International
	2005		2004					2005		2004					2005		2004
	4th		4th		4th Qtr.			4th		4th		4th Qtr.			4th		4th		4th Qtr.
	Qtr.		Qtr.		vs			Qtr.		Qtr.		vs			Qtr.		Qtr.		vs
	$		$		4th Qtr.			$		$		4th Qtr.			$		$		4th Qtr.
Prescription Pharm:		1,904		1,737		10	%		600		584		3	%		1,304		1,153		13	%
Remicade		251		212		19	%		—		—		—			251		212		19	%
PEG-Intron		214		138		55	%		52		42		23	%		162		96		69	%
Nasonex		185		145		27	%		115		81		42	%		70		64		8	%
Temodar		160		150		7	%		73		79		(7	%)		87		72		22	%
Clarinex / Aerius		139		162		(14	%)		76		107		(30	%)		63		55		16	%
Rebetol		94		49		93	%									90		57		57	%
Claritin Rx 1/		85		80		5	%		—		—		—			85		80		5	%
Integrilin		71		81		(12	%)		67		74		(10	%)		4		7		(40	%)
Avelox 2/		68		44		55	%		68		44		55	%		—		—		—
Intron A		66		79		(16	%)		32		29		12	%		34		50		(32	%)
Subutex		49		50		(2	%)		—		—		—			49		50		(2	%)
Caelyx		46		40		13	%		—		—		—			46		40		13	%
Cipro 2/		33		43		(24	%)		33		43		(24	%)		—		—		—
Elocon		32		42		(24	%)		—		9		(99	%)		32		32		(3	%)

1/	Includes international net sales of Claritin Rx only. Canadian net sales of Claritin are reported in the OTC Claritin line within Consumer Health Care.
2/	Includes net sales in Puerto Rico

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
GLOBAL PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th				4th Qtr.			12 Mos.
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		vs			vs
	$		$		$		$		$		$		$		$		$		$		$		$		$		$		4th Qtr.			12 Mos.
Global Prescription Pharm:		1,846		1,975		3,820		1,840		5,660		1,904		7,564		1,481		1,644		3,125		1,556		4,681		1,737		6,417		10	%		18	%
Remicade		220		234		454		237		691		251		942		165		182		347		188		535		212		746		19	%		26	%
PEG-Intron		170		182		352		185		537		214		751		148		144		293		132		425		138		563		55	%		33	%
Nasonex		183		199		382		170		552		185		737		140		156		296		153		449		145		594		27	%		24	%
Temodar		131		145		276		152		428		160		588		86		102		188		121		309		150		459		7	%		28	%
Clarinex / Aerius		144		207		351		157		507		139		646		130		226		356		175		530		162		692		(14	%)		(7	%)
Rebetol		64		91		155		82		237		94		331		99		88		187		52		239		49		287		93	%		15	%
Claritin Rx 1/		111		100		211		76		287		85		371		91		82		173		67		240		80		321		5	%		16	%
Integrilin		75		82		158		86		244		71		315		73		78		151		94		245		81		325		(12	%)		(3	%)
Avelox 2/		73		46		119		41		159		68		228		—		—		—		—		—		44		44		55	%
Intron A		73		75		148		72		220		66		287		69		89		158		81		239		79		318		(16	%)		(10	%)
Subutex		51		53		104		44		148		49		197		44		47		91		45		136		50		185		(2	%)		6	%
Caelyx		43		46		89		46		135		46		181		34		35		70		39		109		40		150		13	%		21	%
Cipro 2/		37		36		72		41		114		33		146		—		—		—		—		—		43		43		(24	%)
Elocon		41		38		79		34		113		32		144		38		46		84		42		127		42		168		(24	%)		(14	%)

1/	Includes international net sales of Claritin Rx only. Canadian net sales of Claritin are reported in the OTC Claritin line within Consumer Health Care.
2/	Includes net sales in Puerto Rico

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
U.S. PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th				4th Qtr.			12 Mos.
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		vs			vs
	$		$		$		$		$		$		$		$		$		$		$		$		$		$		4th Qtr.			12 Mos.
Total U.S. Pharm:		549		609		1,157		597		1,755		600		2,355		411		495		906		518		1,424		584		2,007		3	%		17	%
PEG-Intron		52		38		91		42		132		52		184		63		50		113		49		163		42		205		23	%		(10	%)
Nasonex		109		115		223		109		332		115		447		82		85		167		104		271		81		353		42	%		27	%
Temodar		57		65		122		70		191		73		264		37		45		82		60		142		79		220		(7	%)		20	%
Clarinex / Aerius		67		90		157		93		249		76		325		69		126		195		118		313		107		420		(30	%)		(23	%)
Integrilin		71		78		150		82		232		67		299		68		72		139		88		228		74		301		(10	%)		(1	%)
Avelox 1/		73		46		119		41		159		68		228		—		—		—		—		—		44		44		55	%
Intron A		32		36		68		36		104		32		136		18		33		51		30		81		29		109		12	%		24	%
Cipro 1/		37		36		72		41		114		33		146		—		—		—		—		—		43		43		(24	%)
Elocon		4		2		6		1		7		—		7		7		12		19		12		31		9		40		(99	%)		(83	%)

1/ Includes net sales in Puerto Rico

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
INTERNATIONAL PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th				4th Qtr.			12 Mos.
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		vs			vs
	$		$		$		$		$		$		$		$		$		$		$		$		$		$		4th Qtr.			12 Mos.
Total International Pharm:		1,297		1,366		2,663		1,243		3,905		1,304		5,209		1,070		1,150		2,220		1,037		3,257		1,153		4,410		13	%		18	%
Remicade		220		234		454		237		691		251		942		165		182		347		188		535		212		746		19	%		26	%
PEG-Intron		118		144		261		143		405		162		567		85		94		179		83		262		96		358		69	%		58	%
Nasonex		74		84		159		61		220		70		290		58		71		129		48		178		64		242		8	%		20	%
Temodar		74		80		154		82		237		87		324		49		57		106		61		168		72		239		22	%		35	%
Clarinex / Aerius		77		117		194		64		258		63		321		61		100		161		57		218		55		272		16	%		18	%
Rebetol		70		90		159		80		239		90		330		68		65		133		52		185		57		242		57	%		36	%
Claritin Rx 1/		111		100		211		76		287		85		371		91		82		173		67		240		80		321		5	%		16	%
Integrilin		4		4		8		4		12		4		16		5		6		12		5		17		7		24		(40	%)		(31	%)
Intron A		41		39		80		36		116		34		151		51		56		107		51		158		50		208		(32	%)		(28	%)
Subutex		51		53		104		44		148		49		197		44		47		91		45		136		50		185		(2	%)		6	%
Caelyx		43		46		89		46		135		46		181		34		35		70		39		109		40		150		13	%		21	%
Elocon		37		36		73		33		106		32		137		31		34		65		31		96		32		128		(3	%)		7	%

1/ Canadian net sales of Claritin are reported in the OTC Claritin line within Consumer Health Care.

All figures rounded. Totals may not add due to rounding.

SCHERING-PLOUGH CORPORATION
CHOLESTEROL FRANCHISE SALES
(Dollars in Millions)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th				4th Qtr.			12 Mos.
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		vs			vs
	$		$		$		$		$		$		$		$		$		$		$		$		$		$		4th Qtr.			12 Mos.
Global Zetia: 1/		331		317		648		357		1,004		392		1,396		189		242		431		294		725		328		1,052		19	%		33	%
U.S.		269		240		509		277		785		297		1,082		169		212		381		256		637		274		910		8	%		19	%
International		62		77		139		80		219		95		314		20		30		50		38		88		54		142
Global Vytorin: 1/ 2/		178		201		379		265		644		368		1,012		—		5		5		50		55		75		131
U.S.		157		173		330		229		560		314		874		—		—		—		42		42		59		102
International		21		28		49		36		84		54		138		—		5		5		8		13		16		29
Global Cholesterol: 1/		509		518		1,027		622		1,648		760		2,408		189		247		436		344		780		403		1,183
U.S.		426		413		839		506		1,345		611		1,956		169		212		381		298		679		333		1,012
International		83		105		188		116		303		149		452		20		35		55		46		101		70		171

1/

Substantially all sales of cholesterol products are not included in the Company’s net sales. Global sales include sales under the Merck/Schering-Plough partnership, plus any sales that are not part of the partnership, such as Schering-Plough sales of cholesterol products in Latin America. In the fourth quarter of 2005 and 2004, sales in non-joint venture territories of the cholesterol franchise totaled $5 and $3, respectively. For the twelve months of 2005 and 2004, sales in non-joint venture territories of the cholesterol franchise totaled $19 and $11, respectively.

2/

Vytorin received first regulatory approval in 2004.

The results of the operation of the joint venture are reflected in equity income and have no impact on the Company’s gross and other operating margins.

The company utilizes the equity method of accounting for the joint venture. The cholesterol agreements provide for the sharing of net income/(loss) based upon percentages that vary by product, sales level and country. In the U.S. market, Schering-Plough receives a greater share of profits on the first $300 of annual ZETIA sales. Above $300 of annual ZETIA sales, the companies share profits equally. Schering-Plough’s allocation of joint venture income is increased by milestones earned. Further, either partner’s share of the joint venture’s net income/(loss) is subject to a reduction if the partner fails to perform a specified minimum number of physician details in a particular country. The partners agree annually to the minimum number of physician details by country.

          All figures rounded. Totals may not add due to rounding.

CONSOLIDATED OPERATIONS DATA
(Dollars in Millions)
(Unaudited)

	2005														2004
	1st		2nd		6		3rd		9		4th				1st		2nd		6		3rd		9		4th
	Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year		Qtr.		Qtr.		Mos.		Qtr.		Mos.		Qtr.		Year
	$		$		$		$		$		$		$		$		$		$		$		$		$		$
Geographic Sales
U.S.		897		970		1,866		886		2,752		837		3,589		738		827		1,565		800		2,365		854		3,219
Europe and Canada		1,035		1,102		2,138		927		3,065		976		4,040		874		972		1,846		820		2,666		929		3,595
Latin America		210		218		427		223		650		233		884		174		182		356		204		560		223		782
Pacific Area and Asia		227		242		469		248		717		278		995		177		166		343		154		497		178		676
Consolidated Sales		2,369		2,532		4,900		2,284		7,184		2,324		9,508		1,963		2,147		4,110		1,978		6,088		2,184		8,272

		2005																													2004
		1st				2nd				6				3rd				9				4th								1st				2nd				6				3rd				9				4th
		Qtr.				Qtr.				Mos.				Qtr.				Mos.				Qtr.				Year				Qtr.				Qtr.				Mos.				Qtr.				Mos.				Qtr.				Year
		$				$				$				$				$				$				$				$				$				$				$				$				$				$
Other Expense/(Income), Net
Interest Income	(	$	33	)	(	$	40	)	(	$	74	)	(	$	45	)	(	$	118	)	(	$	58	)	(	$	176	)	(	$	14	)	(	$	15	)	(	$	29	)	(	$	20	)	(	$	50	)	(	$	31	)	(	$	80	)
Interest Expense			45				40				86				36				122				41				163				48				43				91				39				130				38				168
FX Losses			4				1				4				2				6				2				8				1				4				4				0				4				1				5
Other Expense/(Income)			1				(9	)			(7	)			7				(1	)			10				10				1				11				12				15				28				25				53
Total — Other Expense/(Income), Net		$	17		(	$	8	)		$	9			$	0			$	9		(	$	5	)		$	5			$	36			$	43			$	78			$	34			$	112			$	33			$	146

     All figures rounded. Totals may not add due to rounding.

Alex Kelly 908-298-7450